FDA Approves First Generic Rival to Gilead's Yeztugo
RDY sits 27% above its 52-week low of $11.36.
Summary
Dr. Reddy's won FDA approval for the first generic version of Gilead's Yeztugo, a direct competitive threat to a Gilead product. For Dr. Reddy's, this is a fresh US launch opportunity in a market where North America generics revenue just dropped 29% year over year in Q2 FY2026, so a first-to-file style generic adds a needed growth lever. The approval also lands against a rough regulatory stretch: four Form 483s across its Bachupally, Mexico, FTO-11 and FTO-9 sites since mid-August, which keeps manufacturing compliance risk in view. Gilead faces the more consequential side of this — a generic entrant erodes Yeztugo's pricing and exclusivity economics. Watch Dr. Reddy's launch timing and any Gilead response on pricing or litigation.
At the time of this announcement, RDY was trading at $14.38 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.8B. The 52-week trading range was $11.36 to $15.67. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.